Levodopa(L-DOPA)isanendogenousprecursortodopamine,norepinephrine,andepinephrine;itcanalsobefoundinbeanplantssuchasspeciesofMucuna.L-DOPAincreasesbraindopamineconcentrationsandisclinicallyusedtotreatsymptomsofParkinson’sdisease.Peripheralincreasesindopaminecausemanysideeffects,includingdyskinesias,hypotension,andnausea.
| CasNo. | 59-92-7 |
|---|---|
| Purity | ≥98% |
| Formula | C9H11NO4 |
| FormulaWt. | 197.19 |
| ChemicalName | 3-Hydroxy-L-tyrosine |
| IUPACName | (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoicacid |
| Synonym | Bendopa;Dopaflex;Dopaidan;Doparl;Dopaston;Eldopatec;L-DOPA;Maipedopa;Parda;Veldopa |
| MeltingPoint | 276-278°C(dec.) |
| Solubility | Solubleinwater,dilHCl,andformicacid.Practicallyinsolubleinethanol,benzene,chloroformandethylacetate. |
| Appearance | Awhiteorslightlycreamcrystallinepowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| MSDS | L1782MSDSPDF |
|---|---|
| InfoSheet | L1782InfoSheetPDF |
PahwaR,LyonsKE.TreatmentofearlyParkinson"sdisease.CurrOpinNeurol.2014Jun19.[Epubaheadofprint].PMID:24950010.
PdMedCollaborativeGroup.Long-termeffectivenessofdopamineagoNISTsandmonoamineoxidaseBinhibitorscomparedwithlevodopaasinitialtreatmentforParkinson"sdisease(PDMED):alarge,open-label,pragmaticrandomisedtrial.Lancet.2014Jun10.[Epubaheadofprint].PMID:24928805.
